Singular Health Group Ltd

Singular Health Group Ltd has a current ratio of 12.66, indicating strong liquidity with current assets significantly outpacing current liabilities. The company has no long-term debt, and its debt-to-equity ratio is 0.0, suggesting a conservative capital structure with no leverage. However, the company reported negative operating cash flow of -2,341,360 AUD and free cash flow of -6,161,560 AUD, indicating cash outflows from operations and capital expenditures. The company's profitability is weak, with a return on equity of -0.4869 and a return on assets of -0.4488, both significantly below the industry median for advanced medical equipment and technology firms. These metrics suggest the company is not generating returns that meet the cost of equity or assets, which is a concern for investors. Singular Health Group Ltd's revenue is concentrated in a single business segment, as disclosed in its financial statements, with no geographic diversification provided in the available data. This lack of diversification may expose the company to higher operational and market risks if the segment faces challenges. The company's growth trajectory is uncertain, with no specific revenue growth projections provided in the available data. The company reported a revenue of 702,020 AUD, but this is accompanied by a significant operating loss of -6,251,640 AUD and a net loss of -6,376,210 AUD. These figures suggest the company is not currently generating profits and may require additional capital to sustain operations. The risk assessment indicates low liquidity and dilution risk, with no immediate filing-based liquidity or dilution flags detected. The company has no long-term debt and a high current ratio, which supports its liquidity position. However, the negative operating and free cash flows suggest potential future liquidity challenges if the company's financial performance does not improve. Recent events and filings do not indicate any significant changes in the company's operations or financial strategy. The company has not issued any new shares or raised additional capital in the recent period, and there are no notable regulatory or legal issues reported.